JAN 22, 2021 8:17 PM PST

Treating NF1: Investigational Drug Shows Positive Results

WRITTEN BY: Nouran Amin

From preclinical studies, researchers have found that an investigational drug called ‘cabozantinib’ can treat tumors form a genetic disorder known as neurofibromatosis type 1 (NF1).

"This is the second class of drugs to demonstrate a very promising response rate for NF1 patients with these tumors," said first author Fisher, Chief of the Section of Neuro-Oncology and Director of the Neurofibromatosis Program at CHOP, and Group Chair for the NF Clinical Trials Consortium, which includes 25 sites developing innovative biologically-based clinical trials for complications of NF. "Collectively, the data presented in this study illustrate a true bench-to-bedside approach, coordinating translational and clinical efforts to advance targeted therapies for a rare disease like NF1."

NF1 is a rare disease affecting approximately 1 in 3000 people globally and is characterized by a proliferation of tumors throughout the nervous system.

Learn more about NF1:

"It's incredibly exciting that we now have two classes of drugs that result in tumor responses, given that we had no promising agents only a few years ago," Dr. Fisher said. "However, despite this excitement, neither cabozantinib nor MEK inhibitors shrink all tumors or make them go away completely. Therefore, we are building on these results as well as ongoing laboratory studies and are planning future exploration of combination therapies, so that we can further improve outcomes for these patients with these debilitating and life-threatening tumors."

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 21, 2022
Cannabis Sciences
One of the most lucrative skillsets in cannabis
APR 21, 2022
One of the most lucrative skillsets in cannabis
For anyone looking for a well-compensated, in demand job in the cannabis industry, you can't go wrong with becoming an e ...
MAY 07, 2022
Drug Discovery & Development
Ibuprofen and Blood Pressure Medication Linked to Kidney Damage
MAY 07, 2022
Ibuprofen and Blood Pressure Medication Linked to Kidney Damage
A combination of ibuprofen and certain blood pressure medications could lead to acute kidney injury. The corresponding s ...
JUN 02, 2022
Coronavirus
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
JUN 02, 2022
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
It has been clear for some time that loneliness and social isolation can lead to increased risks for adverse h ...
JUN 06, 2022
Immunology
Using Antibodies to Create Potent Cancer Treatments
JUN 06, 2022
Using Antibodies to Create Potent Cancer Treatments
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
JUN 27, 2022
Cancer
A Genomic Scan Detects Cancer-Driving Mutations
JUN 27, 2022
A Genomic Scan Detects Cancer-Driving Mutations
Cancer develops when the DNA in our cells becomes altered, resulting in a gene mutation.  DNA alterations can occur ...
Loading Comments...